In the Boardroom
Refine Search
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Biotechnology
Following a board decision to terminate the mandate of Alexis Vandier, France-based biotech OSE Immunotherapeutics (Euronext: OSE) has appointed Dr Nicholas Poirier as its chief executive, with immediate effect. 8 October 2022
Biotechnology
T-CURX, a CAR-T cell spin-off from the University of Würzburg, has announced the appointment of its co-founder, Ulf Grawunder, as the chief executive of the company. 6 October 2022
Pharmaceutical
LifeMine Therapeutics, a US start-up searching the fungal biosphere for genetically-encoded small molecules (GEMs), today announced the appointments of Martin Stahl, as chief scientific officer and Louis Plamondon, as executive vice president and head of CMC. 6 October 2022
Pharmaceutical
Victor Grifols Roura, who has devoted 50 years to building Spanish plasma-derived drugmaker Grifols (MCE: GRF) in senior roles including chief executive for 30 years, retires as non-executive chairperson. He is designated as chairperson of honor in recognition of his numerous contributions. 5 October 2022
Biotechnology
Dutch neurology-focused genetic medicine company Vico Therapeutics has appointed Scott Schobel as its chief medical officer (CMO). 4 October 2022
Biotechnology
Urica Therapeutics, a Fortress Biotech company focused on the development and commercialization of products for gout and chronic kidney disease, has announced the appointments of Jay Kranzler as chairman and chief executive, and Vibeke Strand to its board of directors. 3 October 2022
Biotechnology
Cambridge, USA-base immuno-oncology company DEM BioPharma has appointment of Nenad Grmusa as chief executive and Christophe Quéva, as chief scientific officer. 27 September 2022
Pharmaceutical
Shares in Canada’s NervGen Pharma closed 8% lower after trading on Friday. 26 September 2022
Biotechnology
Belgium’s NeuVasQ Biotechnologies, a Université Libre de Bruxelles (ULB) spin-off developing pharmaceuticals to restore blood-brain barrier function, has named Emmanuel Lacroix chief executive and company director. 20 September 2022
Biotechnology
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO). 20 September 2022
Biotechnology
Privately-held US CAR-T company ImmPACT Bio has tasked Jonathan Benjamin with leading its clinical development strategy as the company’s chief medical officer. 14 September 2022
Biotechnology
French biotech GenSight Biologics, which is developing gene therapy for rare and neurodegenerative diseases of the eye, is adding to its management team in anticipation of the European commercialization of Lumevoq (lenadogene nolparvovec). 13 September 2022
Pharmaceutical
American president Joe Biden has announced his intent to appoint Dr Renee Wegrzyn as the first director of the Advanced Research Projects Agency for Health (ARPA-H), a new agency established to drive biomedical innovation that supports the health of all Americans. 13 September 2022
Pharmaceutical
Lonza, a major Swiss contract development and manufacturing organization, has appointed Daniel Palmacci as president of its Cell and Gene Division. He will take over the role from Jean-Christophe Hyvert, who will continue to serve as president of Lonza’s Biologics Division. 12 September 2022
Biotechnology
US biotech Vertex Pharmaceuticals today announced that Jonathan Biller has been appointed chief legal officer, effective September 19, 2022. 8 September 2022
Biotechnology
STORM Therapeutics, a UK biotech discovering and developing small molecule therapies targeting RNA modification enzymes for oncology and other diseases, has announced the appointment of Gerald McMahon as president, chief executive and board director. 7 September 2022
Biotechnology
Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC). 6 September 2022
Generics
The retiring Roger Scarlett-Smith is to be replaced as head of UK at Germany’s STADA Arzneimittel (SAZ: Xetra) by Rudolf Bär. 6 September 2022
Pharmaceutical
The Drugs for Neglected Diseases initiative (DNDi) has announced Dr Luis Pizarro as its new executive director, who will replace Bernard Pécoul, who has served in the role for almost 20 years. 5 September 2022
Pharmaceutical
A new chapter opens at privately-held Italian drugmaker Chiesi Farmaceutici as the 11-year tenure of chief executive Ugo Di Francesco, aged 62, comes to a close at the end of 2022. 5 September 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze